Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 36, 2023 - Issue 6
Submit an article Journal homepage
20
Views
0
CrossRef citations to date
0
Altmetric
Original Research: Endocrinology

Progress toward the use of noninsulin antihyperglycemic medications in hospitalized patients

David WenkertDivision of Endocrinology, Baylor Scott & White Medical Center – Temple, Temple, Texas, USACorrespondence[email protected]
, MD, PhD
Page 699 | Received 24 Aug 2023, Accepted 24 Aug 2023, Published online: 05 Sep 2023

  • ElSayed NA, Aleppo G, Aroda VR, et al. 16. Diabetes care in the hospital: standards of care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S267–S278. doi:10.2337/dc23-S016.
  • Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022;107(8):2101–2128. doi:10.1210/clinem/dgac278.
  • Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa1515920.
  • Bicker A, Tatara AW, Solomon EJ, Ji CS. Evaluation of the safety of inpatient empagliflozin in a real-world setting. Proc (Bayl Univ Med Cent). 2023;36(6):693–698. doi:10.1080/08998280.2023.2248866.
  • Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023;5(2):82–90. doi:10.36628/ijhf.2022.0030.
  • Dharia A, Khan A, Sridhar VS, Cherney DZI. SGLT2 inhibitors: the sweet success for kidneys. Ann Rev Med. 2023;74(1):369–384. doi:10.1146/annurev-med-042921-102135.
  • Malik ME, Falkentoft AC, Jensen J, et al. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. Lancet Reg Health Eur. 2023;29:100617. doi:10.1016/j.lanepe.2023.100617.
  • Scheen AJ. Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation. Lancet Reg Health Eur. 2023;29:100627. doi:10.1016/j.lanepe.2023.100627.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.